Market Overview

Roth Capital Upgraded Peregrine Pharma Following Internal Review of Trial

Share:
Related PPHM
US Stock Futures Tumble, China's Shanghai Plunges 8.5%
AstraZeneca, Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial

Roth Capital upgraded Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) following news of an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled trial of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients.

The firm raised its rating from Neutral to Buy and boosted its price target from $1.25 to $2.70.

Latest Ratings for PPHM

DateFirmActionFromTo
Mar 2014McNicoll Lewis VlakMaintainsBuy
Mar 2013Piper JaffrayInitiates Coverage onOverweight
Jan 2013Roth CapitalUpgradesNeutralBuy

View More Analyst Ratings for PPHM
View the Latest Analyst Ratings

Posted-In: News Upgrades Analyst Ratings

 

Related Articles (PPHM)

View Comments and Join the Discussion!

Get Benzinga's Newsletters